Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 1028-1034, 2002;
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, W. J.
Right arrow Articles by Scott, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, W. J.
Right arrow Articles by Scott, M. G.
(Clinical Chemistry. 2002;48:1028-1034.)
© 2002 American Association for Clinical Chemistry, Inc.

Performance of a Revised Cardiac Troponin Method That Minimizes Interferences from Heterophilic Antibodies

Wesley J. Kim1, Omar F. Laterza1, Karl G. Hock1, James F. Pierson-Perry2, Delores M. Kaminski2, Martine Mesguich3, François Braconnier3, Régine Zimmermann3, Martina Zaninotto4, Mario Plebani4, Atef Hanna5, George S. Cembrowski5 and Mitchell G. Scotta1

1 Washington University School of Medicine, Department of Pathology and Immunology, Division of Laboratory Medicine, Box 8118, 660 S. Euclid Ave., St. Louis, MO 63110

2 Dade Behring Inc., Chemistry/Immunochemistry Research and Development, Glasgow Business Community B700, #707, Newark, DE 19714

3 CHU Hôpital Henri Mondor, Laboratoire de Biochimie, 94 Créteil, France

4 Azienda Ospedaliera di Padova, Laboratorio Centrale, Via Giustiniani 1, 35128 Padova, Italy

5 University of Alberta Hospital, Department of Laboratory Medicine and Pathology, 4B1.24 Walter C. MacKenzie Center, 8440 112th St., Edmonton, Alberta, T6G 2B7 Canada

aAuthor for correspondence. Fax 314-362-1461; e-mail mscott{at}labmed wustl.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Background: Recent guidelines for use of cardiac troponin to detect cardiac damage and for cardiovascular risk stratification have made increasingly sensitive troponin assays important. Troponin assays continue to be plagued by interferences caused by heterophilic antibodies (HAs). We evaluated the performance of a revised cardiac troponin I (cTnI) assay designed to have increased analytical sensitivity and to minimize the effect of HAs.

Methods: The revised Dade Behring Dimension® cTnI assay was evaluated according to NCCLS EP5-A at five institutions. Plasma samples from 14 309 patients were assayed by the original Dimension cTnI assay. To identify samples that may have interfering HAs, samples with values >1.4 µg/L were reanalyzed on the Dade Behring Stratus® CS cTnI assay. Samples with possible interfering antibodies were also analyzed before and after selective absorbance studies on the revised Dade Behring Dimension cTnI assay.

Results: The limit of quantification in the revised method was 0.1 µg/L with imprecision (CV) of 11–17% at 0.1 µg/L. Values correlated well with the Stratus CS cTnI method: revised = 1.06(original) + 0.01; r = 0.98, Sy|x = 0.25 µg/L). Falsely increased results consistent with myocardial infarction by the original Dimension cTnI assay and presumably attributable to HAs were identified in 0.17% of all patients with samples submitted for cTnI analysis. The revised Dimension cTnI assay eliminated the interference in 17 of 25 samples identified and greatly decreased the interference in the other 8.

Conclusions: The revised Dimension cTnI method greatly minimizes the effect of interfering HAs. It also exhibits analytical performance characteristics consistent with recent guidelines for use of this assay to detect cardiac damage.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Measurement of cardiac troponins is important for the diagnosis of myocardial infarction and for risk stratification (1)(2)(3)(4)(5). In light of recent European Society of Cardiology/American College of Cardiology (ESC/ACC)1 and National Academy of Clinical Biochemistry (NACB) recommendations for the use of troponins (1)(2) and reports of falsely increased cardiac troponin I (cTnI) values attributable to heterophilic antibodies (HAs) (6)(7)(8), modifications to cTnI methods that increase sensitivity and decrease interferences will be important. HAs can cause interference in immunoassays (6)(7)(8)(9)(10)(11), but the estimated incidence varies tremendously, from 0.2% to 40% (9)(10)(11). In the clinical laboratory, HAs that cross-react with immunoglobulins of different species are of particular interest because they can cross-link the solid phase and soluble antibodies in two-site "sandwich" immunoassays. Because many in vitro diagnostic immunoassays use murine monoclonal antibodies, heterophilic human anti-mouse immunoglobulin antibodies (HAMAs) are of particular concern. Development of HAMAs can follow the use of murine monoclonal antibodies for therapeutic and diagnostic imaging purposes (12). Other proposed etiologies for developing interfering HAs include incidental or occupational exposure to foreign animal proteins (10) and microbial antigens that induce broadly reactive HAs that bind immunoglobulins from other species (8)(13). HAs with anti-immunoglobulin activity can also be found in patients with autoimmune diseases such as rheumatoid arthritis (7)(9).

The presence of HA interferences in immunoassays has led manufacturers to indicate this possibility in package inserts and to add "blocking" agents to their immunoassay formulations (14)(15). Despite these measures, the problem persists (6)(7)(8)(16)(17)(18)(19)(20)(21). Here we examine the incidence of interfering antibodies in the original Dimension cTnI assay and evaluate a revised Dimension cTnI assay designed to be more sensitive and to minimize the effect of interfering HAs.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
cTnI measurements
The revised Dimension RxL cTnI method (Dade Behring) is a two-site sandwich immunoassay that uses the same two monoclonal antibodies specific for the stable central region of the molecule (22) used in the original Dimension RxL cTnI and the Dade Behring Stratus CS methods (23)(24). The same calibrators are used except that the revised Dimension cTnI method uses a human serum-based matrix, whereas the original method used a buffered bovine serum albumin matrix. Calibrator value assignment is based on comparisons with a set of master calibrators containing purified human troponin complex. The revised method incorporates a new, proprietary conjugate reagent formulation, an increased concentration of irrelevant mouse immunoglobulin to minimize HAMA interference, and a smaller sample volume of 50 µL. All assays were used according to the manufacturer’s suggestions. The five evaluation sites were Washington University (St. Louis, MO; site A); CHU Hôpital Henri Mondor (Créteil, France; site B); Azienda Ospedaliera di Padova (Padova, Italy; site C); University of Alberta (Edmonton, Canada; site D); and Dade Behring Research Laboratory (Newark, DE; site E). All sites obtained approval from their institutional review boards.

performance characteristics of the revised dimension cTnI assay
Within-run and total reproducibility were determined using aliquots of MAS Tru-LiquidTM Quality Control (three concentrations) and serum pools. Analysis was performed in duplicate, once a day for 20 days according to the NCCLS EP5-A protocol, and analyzed by ANOVA. Each site calculated their own statistics, and site E calculated the statistics for combined data. Different lots of quality-control material were used at the evaluation sites. To determine precision at lower cTnI concentrations, a precision profile was performed at site C. Eight dilutions of a patient serum sample, with an initial concentration of 0.3 µg/L, were made with the zero calibrator, aliquoted, and frozen. Aliquots from each sample were tested in duplicate for 10 days over a 20-day period.

The minimum detection limit, defined as the lowest concentration that can be differentiated from zero, was determined separately at sites A, B, C, and E by assaying 20 replicates of the revised cTnI zero calibrator at the beginning and end of the 12- to 16-week evaluation period.

Assay range and linearity were determined using pooled serum and plasma samples with increased cTnI concentrations and the Level 5 revised Dimension cTnI calibrator (concentration, 34.4 µg/L). Samples were diluted with the Level 1 calibrator (concentration, 0 µg/L) at sites A, B, C, and E. Each dilution was assayed in triplicate and compared with expected results by linear regression. The lower limit of linearity was determined similarly using a plasma sample containing 1.0 µg/L cTnI. Calibration stability was determined by assaying the five calibrators in triplicate once a week for 9 weeks at site A. Paired serum and lithium-heparin-plasma samples from 135 patients, obtained at sites A (n = 54), B (n = 51), and C (n = 30), were assayed to examine the relationship between serum and plasma cTnI values. The effect of sample quality was examined at site E according to NCCLS guideline EP7 using a sample containing 1.5 µg/L cTnI and up to the indicated concentrations of the following: bilirubin (600 mg/L), hemoglobin (10 g/L), and triglycerides (30 g/L).

reference interval and method comparison
The reference interval for the revised Dimension cTnI method was determined using serum and plasma samples from 342 volunteers or patients (176 males and 166 females; age range, 18–83 years) with no history or evidence of cardiac disease at sites A (n = 121), B (n = 171), and C (n = 50). Values were ranked nonparametrically to estimate the central 95% region and the upper 99 percentile (25).

Results from a total of 234 serum or plasma samples with cTnI values from <0.4 to 209.7 µg/L on the original Dimension cTnI assay were compared with Stratus CS results by linear regression. Results from a total of 618 serum or plasma samples with cTnI values from <0.1 to 220.0 µg/L on the revised Dimension cTnI assay were compared with results from the Stratus CS across all five evaluation sites.

identification and characterization of interfering antibodies
Plasma samples from 14 309 patients were submitted for routine cTnI analysis by the original Dimension cTnI assay between August 14, 2000, and April 11, 2001, at Barnes-Jewish Hospital. Samples with values >=1.4 µg/L were selected for repeat testing by the Stratus CS cTnI method, and those with Stratus CS values <=0.1 µg/L were considered clinically discrepant and chosen for further investigation. We chose 1.4 µg/L as the "cutoff" because this was the value used at our institution (site A) and stated in the original Dimension cTnI assay package insert as being consistent with myocardial infarction. The lower limit for reporting values from the Stratus CS method at site A is 0.1 µg/L. To further investigate the discrepant samples, 150 µL of plasma was mixed with 50 µL of Sepharose-conjugated protein A (Pharmacia), Sepharose-conjugated irrelevant murine IgG1/IgG2a antibodies (murine anti-parathyroid hormone receptor monoclonal antibodies) (26), or unconjugated Sepharose 4B for 16–18 h, with gentle rotation, at room temperature. Discrepant samples were also mixed with 50 µL of HBR reagent (a proprietary HAMA-blocking reagent from Scantibodies, Inc.) or with 50 µL of saline (control) for 2 h, with gentle rotation, at room temperature. After adsorption and removal of the Sepharose beads, samples were analyzed on the original Dimension cTnI assay.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
The within-run imprecision (CV) was 1.0–8.4% and day-to-day total CV was 3.4–15% at sites that performed full precision studies (Table 1 ). CVs >=6.0% were observed only for samples with cTnI values <0.7 µg/L. The imprecision profile at low cTnI concentrations showed a CV of 10% at 0.14 µg/L and 20% at 0.08 µg/L (Fig. 1A ). The minimum detection limit (mean plus 2 SD of zero calibrator) was 0.02 µg/L.


View this table:
[in this window]
[in a new window]
  		Table 1. Precision data for the revised Dimension cTnI assay from three different sites.



View larger version (14K):
[in this window]
[in a new window]
  		Figure 1. Precision profile of the revised Dimension cTnI assay at low cTnI concentrations.

Dilutions of a patient sample were analyzed in duplicate once a day for 20 days, and total precision was plotted against mean cTnI concentration. Dotted line, extrapolation of the concentration producing a CV of 10%; dashed line, extrapolation of the concentration producing a CV of 20%.

Regression analysis of observed and expected values from dilutions of a patient sample (site B) containing 32.10 µg/L cTnI yielded: observed = [0.99(SD, ±0.01) x expected] + 0.29(±0.22); Sx|y = 0.31 µg/L; r = 0.99. Comparable results were obtained at sites A, C, and E, using purified water, saline, and the zero calibrator as the diluent. A comparison of observed vs expected values for dilutions of a plasma sample containing 1.0 µg/L showed that the lower limit of linearity was at least 0.1 µg/L (data not shown). Together, the linearity studies and precision profile produce a linear range for quantification of 0.1–30.0 µg/L. Linear regression analysis of values obtained for the five calibrators, run as unknowns over a period of 9 weeks at site A, showed no significant slope change (P >0.05) at any concentration.

Comparison of values from 135 paired serum and plasma samples showed excellent correlation without significant bias: plasma = [1.00(±0.01) x serum] + 0.03(±0.04); Sx|y = 0.43 µg/L, r = 0.99; Fig. 2A . Less than 10% interference in observed values was observed in samples containing high concentrations of bilirubin (600 mg/L), hemoglobin (10 g/L), or triglycerides (30 g/L). The upper reference values for the revised Dimension cTnI assay were <0.05 µg/L (97.5 percentile) and <0.07 µg/L (99 percentile).



View larger version (19K):
[in this window]
[in a new window]
  		Figure 2. Bland-Altman difference plots for serum vs plasma values for the revised Dimension cTnI assay (A) and for cTnI values from the revised Dimension cTnI assay vs Stratus CS (B).

(A), plasma = [1.00 (±0.01) x serum] + 0.03 (±0.04); Sx|y = 0.43 µg/L; r = 0.99; n = 135. (B), revised = [1.06 (±0.01) x Stratus CS] + 0.01 (±0.01); Sx|y = 0.25 µg/L; r = 0.98. Values in parentheses are SD.

Values from 234 samples measured by the original Dimension cTnI assay showed good correlation with values by the Stratus CS assay across the entire analyte range (r = 0.98; Sx|y = 1.29 µg/L), including a subset of 218 samples with values <10 µg/L (r = 0.96; Sx|y = 0.91 µg/L), but exhibited a proportional bias for all samples (slope, 1.30) and for samples with values <10 µg/L (slope, 1.35) relative to the Stratus CS assay.

Values for 618 samples from the revised Dimension cTnI assay showed excellent agreement with values from the Stratus CS assay (slope, 1.00; r = 0.99; Sx|y = 0.84 µg/L), as well as for a subset of 500 samples with values <5 µg/L (slope, 1.06; r = 0.98; Sx|y = 0.25 µg/L; Fig. 2BUp ). There was consistency in the individual regression analyses at the five testing sites, with slopes ranging from 0.96 to 1.05, intercepts ranging from 0.02 to 0.24, and all r values >=0.99. No statistical outliers were observed at any site.

Of the 14 309 patients with cTnI testing ordered, 1596 patients had at least one cTnI >=1.4 µg/L by the original Dimension assay, and of these, 25 produced a cTnI value <=0.1 µg/L on the Stratus CS assay. Assuming that these 25 discrepant values were attributable to an interfering antibody gives an incidence of 0.17% of all patients with samples submitted for cTnI analysis and 1.6% of patients with a cTnI value>=1.4 µg/L. These 25 patients (13 males and 12 females) ranged in age from 30 to 84 years (mean, 60.9 years). Thirteen patients had documented histories of infectious disease, 13 had endocrine disease, 13 had recent surgery, 9 had cardiac disease, 8 had renal disease, 7 had pulmonary disease, 7 had gastrointestinal disease, 6 had cancer, and 2 had connective tissue disease.

The range of cTnI values on the original Dimension cTnI assay for these 25 patients was 1.6–6.0 µg/L (mean, 2.8 µg/L). Seventeen of the 25 (68%) discrepant patient samples produced a cTnI value <0.1 µg/L on the revised Dimension cTnI assay. However, eight of the discrepant samples still produced detectable cTnI concentrations (0.1–0.4 µg/L) on the revised method. Three of these patients had a history of congestive heart failure, past myocardial infarction, or coronary bypass surgery, whereas the others had no documented history or risk factors for cardiac disease. A sample from the patient previously described by Covinsky et al. (8) as producing a falsely increased cTnI value of 225 µg/L attributable to a monoclonal HAMA also gave a result of <0.1 µg/L by the revised Dimension cTnI method.

Sufficient sample was available to perform adsorption studies on 10 of the 25 discrepant patient samples (Table 2 ). Three other patient samples (samples 26–28), identified by clinicians as possibly discrepant before August 14, 2000, were also studied but not used to calculate incidence. Complete to partial correction of the discrepant values by the Dimension cTnI assay was accomplished by adsorption with either HBR or murine IgG1/IgG2a-Sepharose in all 13 samples, confirming the presence of an interfering antibody with HAMA activity. The four samples that failed to fully correct with either HBR or murine IgG1/IgG2a-Sepharose (samples 4, 7, 11, and 28) may contain interfering antibodies with specificity to other assay components other than mouse immunoglobulin. Incubation with protein A-Sepharose markedly reduced or corrected the interference in 6 of 12 patient samples (samples 1, 2, 3, 5, 26, and 27), suggesting that the HAs were primarily IgG. The remaining six samples (samples 4, 7, 9, 11, 13, and 28) were minimally affected or unaffected by protein A-Sepharose.


View this table:
[in this window]
[in a new window]
  		Table 2. Characterization of the interfering antibodies in discrepant samples measured for cTnI by the original and revised Dimension cTnI assay vs the Stratus CS assay.1


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The revised Dimension cTnI method was evaluated at five sites to assess performance with respect to recent guidelines from the NACB, ESC, ACC, and American Heart Association (1)(2)(3). NACB recommends the use of two decision limits for cTnI, a low limit to identify patients with small amounts of myocardial injury (97.5 percentile cTnI value) and a higher limit consistent with injury to the extent that it meets WHO criteria for diagnosis of acute myocardial infarction (AMI). The ESC and ACC recommend that the cutoff limit should be set at the 99 percentile of results from a population of healthy individuals. These guidelines place the cutoff value for the revised Dimension cTnI assay at 0.1 µg/L. This takes into account the precision profiles at 0.07 µg/L (CV ~17%) and 0.14 µg/L (CV = 10%). At site A, values are rounded to the nearest tenth for reporting so that a cutoff of 0.1 µg/L is used. Analytical sensitivity, or the lowest detectable concentration, for the revised method is 0.02 µg/L, well below the lower cutoff. The AMI cutoff range determined by ROC analysis remained at 0.6–1.5 µg/L, as determined with the original Dade Stratus cTnI assay. The ESC and ACC recommend a CV <10% at the 99 percentile and AMI cutoff. Total precision for the revised method approaches this goal, with CVs of 11–17% at 0.1 µg/L, and exceeds the goal, with CVs of 4–8%, at the ROC-determined cutoff for AMI.

The revised method shows excellent linearity across the analytical range (0.1–30.0 µg/L), calibration stability that is adequate for routine clinical use, and equivalent cTnI values for either heparinized plasma or serum samples, a finding that contrasts with other troponin methods (27)(28)(29). Finally, results obtained by the revised Dimension cTnI assay show good agreement with values from the Stratus CS assay, in contrast to the original Dimension method, which produced higher values than the Stratus method at the time of this evaluation.

We determined that the incidence of falsely increased cTnI results attributable to HAs that were consistent with the ROC cutoff for AMI on the original Dimension cTnI assay was 0.17% of all patients with cTnI samples submitted and 1.6% of all cTnI samples with values >1.4 µg/L. This incidence corresponds to lower estimates of interfering HAs described in the literature. However, the incidence might be higher if samples between 0.4 µg/L (our lowest reported value on the original Dimension method) and 1.3 µg/L were also examined in light of the new ESC/ACC and NACB criteria for myocardial damage (1)(2)(3).

Samples available for further study produced either undetectable or greatly decreased cTnI values after adsorption with HBR or IgG1/IgG2a-Sepharose, suggesting the presence of interfering HAs with HAMA activity, leading to falsely increased cTnI values. Seven samples still produced a significant, albeit reduced, cTnI value after adsorption with HBR, suggesting that some of the heterophilic activity may have been directed against epitopes on other assay components, such as the enzyme-antibody conjugate. Eight of these samples still produced values between 0.01 and 0.4 µg/L in the revised method, suggesting that the modifications may not fully eliminate the interferences. Alternatively, samples may contain HAs and also contain low amounts of cTnI. However, we did not identify any samples with original Dimension values >1.4 µg/L and Stratus CS values >0.1–1.0 µg/L, which would have suggested the presence of both HA interference and low cTnI concentrations. Taken together, our findings demonstrate that the revised Dimension method is very effective in minimizing false-positive results attributable to HAs or HAMAs.

Six of 12 samples showed correction after adsorption with protein A, suggesting that ~50% of these HAs were IgG and the remaining likely contained interfering IgM antibodies, although IgG3 and IgA, which do not bind protein A, cannot be ruled out. This is consistent with other studies documenting both IgG and IgM HAMAs (8)(9)(30). Interestingly, four of the samples containing IgM interfering antibodies showed the least correction with HBR or IgG1/IgG2a-Sepharose (samples 4, 7, 11, and 28). It is possible that these IgM antibodies were induced by recent infection by microorganisms and that they expressed broadly reactive specificity to nonimmunoglobulin components.

In conclusion, although the incidence of interfering HAs is low, clinically discrepant results in immunoassays continue to occur. Because of this, it is important that manufacturers continue to address this issue. One example is the revised Dimension cTnI assay, which reduces the effects of interfering HAs that were recently described for the original version of this method. The revised method also showed good analytical performance and is consistent with recent guidelines put forth by the NACB, ESC, and ACC.


   Acknowledgments
 
This study was supported by Dade Behring, Inc. We are grateful to Dr. M.O. Benoit (CHU Georges Pompidou-Paris, France), Dr. M.P. Brunet-Coulhon (CH Argenteuil, France), Dr. M.J. Bugugnani (CH Saint Germain en Laye, France), Dr. B. Burnat (CHU Saint Antoine-Paris, France), Dr. M. Dehoux (CHU Bichat-Paris, France), and Dr. C. Renard (HIA Percy Clamart, France) for providing patient samples. We also thank Brian McCormack and Tina Shah (Dade Behring Inc.) for technical support.


   Footnotes
 
1 Nonstandard abbreviations: ESC, European Society of Cardiology; ACC, American College of Cardiology; NACB, National Academy of Clinical Biochemistry; cTnI, cardiac troponin I; HA, heterophilic antibody; HAMA, human anti-mouse immunoglobulin antibody; and AMI, acute myocardial infarction.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Wu AHB, Apple FS, Gibler WB, Jesse RJ, Warshaw MM, Valders R. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery disease. Clin Chem 1999;45:1104-1121.[Abstract/Free Full Text]
  2. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000;36:959-969.[Free Full Text]
  3. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000;36:970-1062.[Free Full Text]
  4. Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001;38:987-990.[Free Full Text]
  5. Fleming SM, Daly KM. Cardiac troponins in suspected acute coronary syndrome. Cardiology 2001;95:66-73.[ISI][Medline] [Order article via Infotrieve]
  6. Fitzmaurice TF, Brown C, Rifai N, Wu AHB, Yeo KTJ. False increase of cardiac troponin I with heterophilic antibodies. Clin Chem 1998;44:2212-2214.[Free Full Text]
  7. Dasgupta A, Banjiree SK, Datta P. False positive troponin I in the MEIA due to the presence of rheumatoid factors in serum. Am J Clin Pathol 1999;112:753-756.[ISI][Medline] [Order article via Infotrieve]
  8. Covinsky M, Laterza O, Pfeifer JD, Farkas-Szallasi T, Scott MG. An IgM {lambda} antibody to Escherichia coli produces false-positive results in multiple immunometric assays. Clin Chem 2000;46:1157-1161.[Abstract/Free Full Text]
  9. Boscato LM, Stuart MC. Incidence and specificity of interference in two-site immunoassays. Clin Chem 1986;32:1491-1495.[Abstract/Free Full Text]
  10. Kricka LJ. Human anti-animal antibody interference in immunologic assays. Clin Chem 1999;45:942-956.[Abstract/Free Full Text]
  11. Thompson RJ, Jackson AP, Langlios N. Circulating antibodies to mouse monoclonal immunoglobulins in normal subjects—incidence, species specificity, and effects on a two-site assay for creatine kinase-MB isoenzyme. Clin Chem 1986;32:476-481.[Abstract/Free Full Text]
  12. Carey G, Lisi PJ, Schroeder TJ. The incidence of antibody formation to OKT3 consequent to its use in organ transplantation. Transplantation 1995;60:151-158.[ISI][Medline] [Order article via Infotrieve]
  13. Posnet DN, Edinger J. When do microbes stimulate rheumatoid factor?. J Exp Med 1997;185:1721-1723.[Free Full Text]
  14. Vaidya HC, Beatty GB. Eliminating interference from heterophilic antibodies in a two-site immunoassay for creatinine kinase MB by using Fab conjugate and polyclonal mouse IgG. Clin Chem 1992;38:1737-1742.[Abstract/Free Full Text]
  15. Yeo KT, Storm CA, Li Y, Jayne JE, Brough T, Quinn-Hall KS, et al. Performance of the enhanced Abbott AxSYM cardiac troponin I reagent in patients with heterophilic antibodies. Clin Chim Acta 2000;292:13-23.[ISI][Medline] [Order article via Infotrieve]
  16. Turpeinen U, Lehtovirta P, Stenman UH. CA125 determined by three methods in samples from patients with human anti-mouse antibodies (HAMA). Clin Chem 1995;41:1667-1669.[Free Full Text]
  17. Cole LA, Rinne KM, Shahabi S, Omrani A. False positive hCG assay result leading to unnecessary surgery and chemotherapy and needless occurrences of diabetes and coma. Clin Chem 1999;45:313-314.[Free Full Text]
  18. Sosolik RC, Hitchcock CL, Becker WJ. Heterophilic antibodies produce spuriously elevated concentrations of the MB isoenzyme of creatine kinase in a selected patient population. Am J Clin Pathol 1997;107:506-510.[ISI][Medline] [Order article via Infotrieve]
  19. Benoist JF, Orbach D, Biou D. False increase in C-reactive protein attributable to heterophilic antibodies in two renal transplant patients treated with rabbit anti-lymphocyte globulin. Clin Chem 1998;44:1980-1985.[Abstract/Free Full Text]
  20. Ingels M, Rangan C, Mortin JP, Williams SR, Clark RF. Falsely elevated digoxin level of 45.9 µg/L due to interference from human antimouse antibody. J Toxicol Clin Toxicol 2000;38:343-345.[ISI][Medline] [Order article via Infotrieve]
  21. Willman JH, Martins TB, Jaskowski TD, Hill HR, Litwin CM. Heterophile antibodies to bovine and caprine proteins causing false-positive human immunodeficiency virus type 1 and other enzyme-linked immunosorbent assay results. Clin Diagn Lab Immunol 1999;6:615-616.[Abstract/Free Full Text]
  22. Bodor GS, Porter S, Landt Y, Ladenson JH. Development of monoclonal antibodies for an assay of cardiac troponin-I and preliminary results in suspected cases of myocardial infarction. Clin Chem 1992;38:2201-2214.
  23. Hafner G, Peetz D, Dati F, Post F, Blankenberg S, Peivandi AA, et al. Analytical and clinical evaluation of Troponin I determination on the Dimension RxL-HM. Clin Chem Lab Med 2000;38:355-361.[ISI][Medline] [Order article via Infotrieve]
  24. Heeschen C, Goldman BU, Langenbrink L, Matschuck G, Hamm CW. Evaluation of a rapid whole blood ELISA for quantification of troponin I in patients with acute chest pain. Clin Chem 1999;45:1789-1796.[Abstract/Free Full Text]
  25. Solberg HE. Establishment and use of reference values. Burtis CA Ashwood ER eds. Tietz textbook of clinical chemistry, 3rd ed. 1999:336-356 WB Saunders Philadelphia. .
  26. Iezzoni JC, Bruns ME, Frierson HF, Scott MG, Pence RA, Defios LJ, et al. Co-expression of parathyroid hormone-related protein and its receptor in breast carcinoma: a potential autocrine effector system. Mod Pathol 1998;11:265-270.[ISI][Medline] [Order article via Infotrieve]
  27. Wu AHB, Feng YJ, Moore R, Apple FS, McPherson PH, Buechler KF, et al. Characterization of cardiac troponin subunit release into serum following acute myocardial infarction, and comparison of assays for troponin T and I. American Association for Clinical Chemistry Subcommittee on cTnI standardization. Clin Chem 1998;44:1198-1208.[Abstract/Free Full Text]
  28. Stiegler H, Fischer Y, Vazquez-Jienez JF, Graf J, Filzmaier K, Fausten B, et al. Lower cardiac troponin T and I results in heparin-plasma than in serum. Clin Chem 2000;46:1338-1344.[Abstract/Free Full Text]
  29. Gerhardt W, Gunnar N, Herbert AK, Burzell BL, Isaksson A, Gustavsson E, et al. Troponin T and I assays show decreased concentrations in heparin plasma compared with serum: lower recoveries in early than in late phases of myocardial injury. Clin Chem 2000;46:817-821.[Abstract/Free Full Text]
  30. McCarthy RC, Ryan FJ, McKenzie CM. Interferences in immunoenzymometric assays caused by IgM anti-mouse IgG antibodies. Arch Pathol Lab Med 1988;112:901-907.[ISI][Medline] [Order article via Infotrieve]



The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
C. A. Parvin and F. S. Apple
The authors of the article cited above respond:
Clin. Chem., August 1, 2006; 52(8): 1608 - 1609.
[Full Text] [PDF]

Home page
 NeurologyHome page
A. Hays and M. N. Diringer
Elevated troponin levels are associated with higher mortality following intracerebral hemorrhage
Neurology, May 9, 2006; 66(9): 1330 - 1334.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. D. Newman, P. B. Bergman, J. C.G. Doery, and N. D.H. Balazs
Factitious increase in thyrotropin in a neonate caused by a maternally transmitted interfering substance.
Clin. Chem., March 1, 2006; 52(3): 541 - 542.
[Full Text] [PDF]

Home page
 ChestHome page
J.-P. Quenot, G. Le Teuff, C. Quantin, J.-M. Doise, M. Abrahamowicz, D. Masson, and B. Blettery
Myocardial Injury in Critically Ill Patients: Relation to Increased Cardiac Troponin I and Hospital Mortality
Chest, October 1, 2005; 128(4): 2758 - 2764.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. Roongsritong, I. Warraich, and C. Bradley
Common Causes of Troponin Elevations in the Absence of Acute Myocardial Infarction: Incidence and Clinical Significance
Chest, May 1, 2004; 125(5): 1877 - 1884.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. M. Preissner, D. J. O'Kane, R. J. Singh, J. C. Morris, and S. K. G. Grebe
Phantoms in the Assay Tube: Heterophile Antibody Interferences in Serum Thyroglobulin Assays
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3069 - 3074.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Panteghini and F. Pagani
On the Comparison of Serum and Plasma Samples in Troponin Assays
Clin. Chem., May 1, 2003; 49(5): 835 - 836.
[Full Text]

Home page
 Clin. Chem.Home page
R. M. Dorizzi, M. Caputo, A. Ferrari, L. Lippa, and P. Rizzotti
Comparison of Serum and Heparin-Plasma Samples in Different Generations of Dimension Troponin I Assay
Clin. Chem., December 1, 2002; 48(12): 2294 - 2296.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, W. J.
Right arrow Articles by Scott, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, W. J.
Right arrow Articles by Scott, M. G.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS